Novartis Ag (NVS) Long-Term Debt Issuances (2010 - 2026)

Novartis Ag has disclosed Long-Term Debt Issuances across 13 years of filings, most recently posting $2.0 billion for Q2 2026.

• In Q2 2026, Long-Term Debt Issuances changed N/A year-over-year to $2.0 billion; the TTM figure through Jun 2026 stood at $15.5 billion (changed N/A YoY), while the FY2025 annual figure was $6.1 billion, down 0.73% from the prior year.
• Long-Term Debt Issuances came in at $2.0 billion for Q2 2026 at Novartis Ag, down from $10.9 billion in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $10.9 billion in Q1 2026 to a low of $3.0 million in Q2 2022.
• Average Long-Term Debt Issuances over 5 years is $2.7 billion, with a median of $2.2 billion recorded in 2024.
• Year-over-year, Long-Term Debt Issuances soared 61725.0% in 2024 and tumbled 96.32% in 2025.
• Over 5 years, Long-Term Debt Issuances stood at $3.0 million in 2022, then surged by 33.33% to $4.0 million in 2023, then soared by 61725.0% to $2.5 billion in 2024, then slumped by 94.54% to $135.0 million in 2025, then soared by 1368.15% to $2.0 billion in 2026.
• Per Business Quant data, the three most recent Long-Term Debt Issuances figures were $2.0 billion in Q2 2026, $10.9 billion in Q1 2026, and $135.0 million in Q3 2025.